Posters

Ranibizumab in diabetic macular oedema: 2 year audit data

Poster Details

First Author: E. Dorairaj UK

Co Author(s): N. Chittajallu   P. Prakash                 

Abstract Details

Purpose:

To determine the visual acuity (VA) outcomes, injection frequency of Ranibizumab in patients with diabetic macular oedema (DMO) treated in Princess Alexandra Hospital (PAH), Harlow. To determine the efficacy of ‘Treat and Extend’ (T&E) regimen and to compare our data with RETAIN study.

Setting:

The study was performed in a district general hospital in the United Kingdom.

Methods:

This data was collected for patients attending Eye Clinic in Princess Alexandra Hospital, Harlow from 2014 to 2015. Retrospective systematic review and analysis of patient data was carried by use of Medisoft. 193 patients and 267 eyes were injected with Ranibizumab as per National Institute of Clinical Excellence criteria for DMO. Outcomes presented include first eye only, treated with ranibizumab monotherapy on Treat and Extend regimen.

Results:

Median number of visits over 24 months: 5 ( month 6), 3( month 12), 4( month 18) and 2 (month 24) Median VA changes from baseline : Stability in VA gains observed for overall cohort of patients, with VA gains of 16 ETDRS letters at month 24. VA improved as early as month 3. The gain in VA was 6 letters in our study as compared to 6.8 in RETAIN study. However at 24 months our patients achieved 7 letter gain in VA. Clinic attendance in PAH was 14 visits through 24 months vs 12.5 observed in RETAIN study. .

Conclusions:

Increasing demands of ophthalmology clinics require frequent evaluations and analysis of the current performance. PAH eye clinic experiences increased number of DMO patients who require frequent injections and follow up visits. The current regimen used is Treat and Extend, which was implemented in 2014 following the update in Ranibizumab license. The switch to current (T&E) regimen offered reduction in number of visits when compared to monthly Pro re nata (PRN) previously used. In addition patients gained and maintained their VA irrespective of baseline VA group highlighting efficacy of current regimen at 24 months.

Financial Disclosure:

None